YESFAL

About Us

Markets

Co-Developments

Contact

YESFAL

Co-developments

Co-developments

Optimal Partnerships

At the heart of our success lies the synergy between Yesfal and Milltons. These two entities operate in harmony, each contributing distinct expertise to form a comprehensive solution; offering a clear sustained and fast ROI.

Research and Development

Research and Development

Research and Development

Milltons

Milltons

Milltons

Researches chronic complications with Northern European Universities (Denmark, Sweden and Norway).

Creates new medical protocols and/or new products.

Creates markets by mass diagnosing an underdiagnosed population.

From concept to patient

in record time

From concept to patient

in record time

Simple three-step process:

Simple three-step process:

Simple three-step process:

Define an unmet need; involve patients at scale along with multiple universities in the research.

Define an unmet need; involve patients at scale along with multiple universities in the research.

Co-create a better solution (better diagnosis, better protocols, and a finished product), again involving the patient and their physicians in the process.

Launch in as many Yesfal markets as possible.

Product case study

Enzymax Business Case

Unmet need

Unmet need

+Supply Shortages: Increasing global shortages of Pancreatin (digestive enzymes used for chronic digestive complications).

+Growing market: Severe increase in prevalence of chronic digestive complications requiring digestive enzymes.

Unmet need

+Supply Shortages: Increasing global shortages of Pancreatin (digestive enzymes used for chronic digestive complications).

+Growing market: Severe increase in prevalence of chronic digestive complications requiring digestive enzymes.

Co-Development

Co-Development

with Aora health

with Aora health

With Aora Health, we co-developed a new generation of Pancreatic Enzyme Replacement Therapy (PERT) using a double capsule (dual release) food supplement that starts its activity in the stomach. Studies have confirmed the superiority of Enzymax* compared to pancreatin.

*Vegan, compared to pork-extracted Pancreatin.

Grow your audience

Co-Development

with Aora health

With Aora Health, we co-developed a new generation of Pancreatic Enzyme Replacement Therapy (PERT) using a double capsule (dual release) food supplement that starts its activity in the stomach. Studies have confirmed the superiority of Enzymax* compared to pancreatin.

*Vegan, compared to pork-extracted Pancreatin.

Grow your audience

Aora conducted In-vitro study (Valencia Polytechnic University):

• On average 280% more effective than pancreatin. • 6 times more consistent in enzymatic activity.

Learn more

Aora conducted In-vitro study (Valencia Polytechnic University):

• On average 280% more effective than pancreatin. • 6 times more consistent in enzymatic activity.

Learn more

Aora conducted In-vitro study (Valencia Polytechnic University):

• On average 280% more effective than pancreatin. • 6 times more consistent in enzymatic activity.

Learn more

Milltons conducted in-vivo study:

• On average 80% more effective in Vivo (mainly because the digestion starts in the stomach, hours earlier than pancreatin). • 50% reduction of painful symptoms.

Learn more

Milltons conducted in-vivo study:

• On average 80% more effective in Vivo (mainly because the digestion starts in the stomach, hours earlier than pancreatin). • 50% reduction of painful symptoms.

Learn more

Milltons conducted in-vivo study:

• On average 80% more effective in Vivo (mainly because the digestion starts in the stomach, hours earlier than pancreatin). • 50% reduction of painful symptoms.

Learn more

Make a living with subs

Commercial superiority of our co-development model

Commercial superiority of our co-development model

(Milltons & Yesfal):

(Milltons & Yesfal):

Enzymax is six years old and is already licensed to 21 markets.

Today, Enzymax is licensed to 5 major Pharmaceutical Corporations.

Make a living with subs

Commercial superiority of our co-development model

(Milltons & Yesfal):

Enzymax is six years old and is already licensed to 21 markets.

Today, Enzymax is licensed to 5 major Pharmaceutical Corporations.

  • Philippines

  • KSA

  • Ukraine

  • Bolivia

  • Ecuador

Collaborate on Innovation

Collaborate on Innovation

If you have a transformative project proposal, we're keen to explore. We are actively building partnerships in neurodegeneration research, diagnostics and treatments.

If you have a transformative project proposal, we're keen to explore. We are actively building partnerships in neurodegeneration research, diagnostics and treatments.

Share Your Proposal with Us Today